The addition of everolimus, an mTOR inhibitor, to an aromatase inhibitor in patients with hormone receptor positive metastatic breast cancer and to trastuzumab and vinorelbine in patients with HER2-positive breast cancer led to improved survival outcomes in randomized placebo-controlled phase III trials (65, 66). Here, ERBB2 is linked to breast carcinoma.